KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Equity Ratio (2016 - 2025)

Sarepta Therapeutics has reported Equity Ratio over the past 15 years, most recently at 0.34 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.34 for Q4 2025, down 11.67% from a year ago — trailing twelve months through Dec 2025 was 0.34 (down 11.67% YoY), and the annual figure for FY2025 was 0.34, down 11.67%.
  • Equity Ratio for Q4 2025 was 0.34 at Sarepta Therapeutics, down from 0.38 in the prior quarter.
  • Over the last five years, Equity Ratio for SRPT hit a ceiling of 0.39 in Q4 2024 and a floor of 0.12 in Q4 2022.
  • Median Equity Ratio over the past 5 years was 0.27 (2022), compared with a mean of 0.27.
  • Biggest five-year swings in Equity Ratio: crashed 58.26% in 2022 and later soared 113.92% in 2023.
  • Sarepta Therapeutics' Equity Ratio stood at 0.29 in 2021, then plummeted by 58.26% to 0.12 in 2022, then surged by 113.92% to 0.26 in 2023, then surged by 46.44% to 0.39 in 2024, then dropped by 11.67% to 0.34 in 2025.
  • The last three reported values for Equity Ratio were 0.34 (Q4 2025), 0.38 (Q3 2025), and 0.37 (Q2 2025) per Business Quant data.